American Capital Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
American Capital Advisory's ACAD Position: Q3 2026 in Review
American Capital Advisory held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 13 shares worth $262. The position accounts for ﹤0.01% of the portfolio, ranked #1033.
American Capital Advisory first reported a position in ACAD in Q2 2026 and has held it in 2 quarters since. The position peaked at $329 in Q2 2026. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- American Capital Advisory held 13 shares of Acadia Pharmaceuticals worth $262 as of Q3 2026.
- American Capital Advisory left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
- Acadia Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q3 2026, its #1033 holding.
- American Capital Advisory first reported a position in Acadia Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
- American Capital Advisory's Acadia Pharmaceuticals position peaked at $329 in Q2 2026.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on American Capital Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.